Isomorphic Laboratories — Cyborg Score 9/10

Exceptional
AI-driven drug discovery platforms

Strategic Profile

The company describes itself as an integrated drug design and development business built around its proprietary AI drug design engine, IsoDDE—not a licensable software platform but a unified drug design engine. Isomorphic Labs maintains strategic partnerships with industry leaders like Novartis, Lilly, and Johnson.

Cyborg Score Rationale

The company secured $2.1 billion in Series B funding (May 2026) led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, demonstrating strong investor confidence. Total external funding now stands at approximately $2.7 billion since inception. The $2.1 billion Series B marks one of the largest financings yet for an AI-first drug discovery company.

Top Insights

  • Industry reports suggest the company is targeting its first human clinical trials by late 2026, although earlier expectations had pointed to an end-2025 timeline. Clinical trial data will be critical proof point for AI-designed medicine viability.
  • As of June 30, 2026, Isomorphic Labs has 403 employees. Expansion reflects accelerated hiring in AI, engineering, drug design, and clinical talent following Series B close (May 2026).
  • Top competitors include Schrodinger, Recursion Pharmaceuticals, and XtalPi. Isomorphic Labs ranks 4th amongst 175 active competitors, of which 68 are funded.

Named Competitors

  • Schrödinger Platform — Physics-based computational platform for drug discovery and materials science
  • Recursion AI Drug Discovery — Biotech company using AI and biology to discover drugs
  • XtalPi AI Drug Design — AI-powered drug discovery and molecular design platform

Recent Developments

  • (May 2026) Raised $2.1 billion Series B funding led by Thrive Capital with sovereign wealth fund participation
  • (February 2026) Published research on IsoDDE capabilities demonstrating biomolecular interaction predictions
  • (May 2025) Closed $600 million Series A funding round from Thrive Capital and Google Ventures

Open the full interactive Isomorphic Laboratories report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →